1182358-83-3

Basic information

• Product Name: 5-(hydroxyMethyl)-4-Methyl-2H-1,2,4-triazol-3(4H)-one
• Synonyms: 5-(hydroxyMethyl)-4-Methyl-2H-1,2,4-triazol-3(4H)-one;5-(Hydroxymethyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one;3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-(hydroxymethyl)-4-methyl-;3-(hydroxymethyl)-4-methyl-1H-1,2,4-triazol-5(4H)-one
• CAS NO: 1182358-83-3
• Molecular Formula: C4H7N3O2
• Molecular Weight: 129.11728
• Mol File: 1182358-83-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• PKA: 8.35±0.20(Predicted)
• CAS DataBase Reference: 5-(hydroxyMethyl)-4-Methyl-2H-1,2,4-triazol-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(hydroxyMethyl)-4-Methyl-2H-1,2,4-triazol-3(4H)-one(1182358-83-3)
• EPA Substance Registry System: 5-(hydroxyMethyl)-4-Methyl-2H-1,2,4-triazol-3(4H)-one(1182358-83-3)

Safety Data

• Hazardous Substances Data: 1182358-83-3(Hazardous Substances Data)

Usage

General Description

5-(hydroxyMethyl)-4-Methyl-2H-1,2,4-triazol-3(4H)-one, also known as Zolmitriptan, is a pharmaceutical compound commonly used as a selective serotonin receptor agonist. It is primarily used in the treatment of migraines, as it works by helping to reduce the swelling of blood vessels in the brain, which in turn relieves headache pain, nausea, sensitivity to light and sound, and other migraine symptoms. Zolmitriptan is available in various forms, including tablets, orally disintegrating tablets, and nasal sprays, and is generally well-tolerated by patients when used as directed by a healthcare professional. It should be noted, however, that misuse or overuse of this compound can lead to serious health complications, so it is important to follow dosage instructions carefully.

Upstream product

• 7397-62-8 butyl glycolate 
• 624-83-9 methyl isocyanate 
• 1613307-26-8 2-(2-hydroxyacetyl)-N-methylhydrazinecarboxamide 
• 1338226-20-2 5-[(benzyloxy)methyl]-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one 

Relevant articles and documents

2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH

The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Heteroaromatic compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salt